“The agreements include the addition of one of the world’s leading pharmaceutical companies to Avid’s growing list of customers, as well as the expansion of the relationship with one of the company’s existing biotechnology customers,” Kinjerski said on the call She added that on top of revenue generated by expanded client relationships, “new project wins from existing customers are incredibly valuable for several reasons. “Early phase projects represent opportunity for manufacturing work up to and including commercial production, onboarding follow-on molecules from existing customers, maybe later phased, leading to validation in commercial stage with more certainty and providing assurance of need for long-term manufacturing.” The quarter also saw Avid complete a client’s process validation campaign for a scaled up manufacturing process in anticipation of future commercial manufacturing, representing the prospect of future commercial business. “Once the process validation is completed, the associated specifications of that process are incorporated into global regulatory filings, if approved. The customers then required to manufacture in a specified facility using that specified process,” said Kinjerski. “Therefore, for those products approved using processes validated at Avid, it’s anticipated that the commercial manufacturing will be conducted at Avid. For this reason, we see each process validation completed today as a great opportunity to build commercial business in the future.”
Market Data 
Markets 
AI
